Key result
Preoperative myocardial viability assessment by CMR did not predict postoperative left ventricular ejection fraction improvement (57.1% in nonviable vs 60.3% in viable without fibrosis) or 3-year survival.
Why the study?
The predictive value of myocardial viability assessed by cardiac magnetic resonance imaging in ischemic cardiomyopathy patients undergoing CABG is uncertain.
Does myocardial viability assessed by CMR predict LVEF improvement or 3-year survival in patients with ischemic cardiomyopathy undergoing CABG?
Cohort (n=106)
No
Does myocardial viability assessed by CMR predict LVEF improvement or 3-year survival in patients with ischemic cardiomyopathy undergoing CABG?
Myocardial viability assessment by CMR does not predict LVEF improvement or 3-year survival after CABG in patients with ischemic cardiomyopathy, suggesting nonviability should not contraindicate surgery.
Answers are grounded in this paper and cite their sources.
CMR viability testing does not inform CABG outcomes in ischemic cardiomyopathy; leaves open its role in surgical selection pending larger prospective data.
Background: The predictive value of myocardial viability assessed by cardiac magnetic resonance imaging (CMR) in patients with ischemic cardiomyopathy undergoing coronary artery bypass grafting (CABG) is uncertain. Other assessment modalities have not shown a correlation between viability and post-CABG survival. Methods: Patients from a single institution between 2014 and 2022 with ischemic cardiomyopathy who were undergoing isolated CABG and who had preoperative CMR viability assessment were included. Patients were grouped by left anterior descending artery territory viability: 0% fibrosis, 25% to 50% fibrosis, and 75% to 100% fibrosis. Primary outcomes were postoperative improvement in left ventricular ejection fraction and 3-year survival. Analyses were adjusted for The Society of Thoracic Surgeons Predicted Risk of Morbidity or Mortality scores. Results: A total of 106 patients met inclusion criteria, and they were divided into 3 groups by myocardial viability. There were no significant differences in preoperative or operative factors among the groups. Left ventricular ejection fraction improvement was seen in 60.3% of patients in the viable without fibrosis group, 79.0% of patients in the viable with fibrosis group, and 57.1% of patients in the nonviable group. Adjusted odds ratios of ejection fraction improvement among the groups demonstrated no significant differences. Similarly, there were no differences in patient survival by 3 years after CABG on Kaplan-Meier analysis. Conclusions: Myocardial viability assessment by CMR for patients with ischemic cardiomyopathy who are undergoing surgical revascularization does not predict left ventricular functional improvement or 3-year survival. Our data suggest that nonviable left anterior descending artery territory as assessed by CMR should not be a contraindication to CABG in otherwise appropriate surgical candidates.
No takes yet. Share an insight, caveat, or question.
Lodhi et al. (2025) conducted a cohort in Ischemic cardiomyopathy undergoing coronary artery bypass grafting (n=106). Myocardial viability assessment by CMR vs. Different degrees of myocardial viability/fibrosis was evaluated on Postoperative improvement in left ventricular ejection fraction and 3-year survival. Preoperative myocardial viability assessment by CMR did not predict postoperative left ventricular ejection fraction improvement (57.1% in nonviable vs 60.3% in viable without fibrosis) or 3-year survival.
Synapse has enriched 10 related papers. Consider them for comparative context: